Sei Investments Co. Boosts Position in Adaptive Biotechnologies Corporation $ADPT

Sei Investments Co. raised its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 77.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 560,554 shares of the company’s stock after buying an additional 243,985 shares during the quarter. Sei Investments Co.’s holdings in Adaptive Biotechnologies were worth $7,780,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ADPT. AQR Capital Management LLC raised its holdings in shares of Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after purchasing an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the last quarter. Caxton Associates LLP acquired a new stake in Adaptive Biotechnologies during the 1st quarter worth about $93,000. New York State Common Retirement Fund grew its position in Adaptive Biotechnologies by 39.2% during the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after purchasing an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Adaptive Biotechnologies by 728.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after buying an additional 333,379 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive raised its 2026 MRD revenue outlook to $268 million-$278 million and outlined plans to separate the MRD business. Management and analysts view the transaction as a potential way to create a focused, higher-growth “pure-play” company and unlock shareholder value. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: Second-quarter revenue was approximately $71.6 million, above the roughly $65.4 million consensus estimate and up 21.5% year over year. Zacks also reported an adjusted loss of $0.10 per share, narrower than the expected $0.13 loss and the $0.17 loss in the prior-year quarter. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analysts raised their targets after the results: TD Cowen increased its target to $28 and maintained a Buy rating, while BTIG lifted its target to $25 and also retained a Buy rating. Analyst price-target coverage
• Neutral Sentiment: Zacks noted that ADPT’s 52-week-high performance reflects improving fundamentals, but investors must assess whether revenue growth, margins and the MRD separation can support additional appreciation. Adaptive Biotechnologies Hit a 52 Week High
• Negative Sentiment: Morgan Stanley raised its target only to $22 and kept an Equal Weight rating, implying limited upside at recent trading levels. The company remains unprofitable, and reported GAAP results included a larger-than-consensus quarterly loss, highlighting ongoing execution and profitability risks.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 492,400 shares of the stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the transaction, the insider owned 812,058 shares in the company, valued at approximately $17,775,949.62. This represents a 37.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total value of $198,000.00. Following the completion of the sale, the insider directly owned 416,775 shares in the company, valued at approximately $7,501,950. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,305,787 shares of company stock worth $27,828,563. 5.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ADPT has been the subject of several analyst reports. JPMorgan Chase & Co. decreased their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Morgan Stanley raised their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday. Guggenheim lifted their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Finally, TD Cowen upped their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $23.33.

Adaptive Biotechnologies Price Performance

ADPT opened at $22.57 on Monday. The company has a fifty day moving average of $19.43 and a two-hundred day moving average of $16.65. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of -55.05 and a beta of 2.08. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.96 and a fifty-two week high of $24.57. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, July 28th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. During the same period in the previous year, the company earned ($0.17) earnings per share. The company’s revenue was up 21.5% compared to the same quarter last year. On average, research analysts expect that Adaptive Biotechnologies Corporation will post -0.43 earnings per share for the current year.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.